Wonder Drug? The GLP-1 Story · Episode 3 of 6 · 22 min
Beyond the Waistline
A class of drugs built to quiet appetite turned out, trial by trial, to protect the heart, kidneys, liver and airway, often more than weight loss alone explains. The episode follows that evidence outward and considers whether reduced chronic inflammation ties it together, while naming the risks plainly.
Who's who
- Daniel Drucker+2 more episodesGLP-1 scientist whose lab turned toward inflammation and immunology
- A. Michael Lincoff+1 more episodeLead investigator of the SELECT cardiovascular trial
- Vlado PerkovicLead investigator of the FLOW kidney trial
- Steven NissenCo-author of the 2007 rosiglitazone analysis that began the outcomes-trial era
- Kathy WolskiCo-author of the 2007 rosiglitazone heart-risk meta-analysis
Timeline
- 2007Nissen and Wolski link the diabetes drug rosiglitazone to increased heart-attack risk
- 2008FDA requires new type 2 diabetes drugs to run cardiovascular outcome trials
- 2016LEADER and SUSTAIN-6 report cardiovascular benefit, an unexpected payoff
- March 8, 2024FDA approves Wegovy to reduce major cardiovascular events, a first for a weight-loss drug
- December 20, 2024FDA approves Zepbound for obstructive sleep apnea in adults with obesity
- August 15, 2025FDA grants accelerated approval of Wegovy for MASH with moderate-to-advanced fibrosis
Still debated
How much of the benefit comes from weight loss and how much is independent of it is estimated, not settled. Inflammation as the unifying mechanism is promising but early, and the MASH approval rests on surrogate markers awaiting long-term outcomes.
